Instituto Valenciano de Fertilidad

IVI (Instituto Valenciano de Infertilidad) is a global leader in reproductive medicine and assisted human reproduction. Established in 1990 as the first medical institution in Spain fully dedicated to assisted reproduction, it has grown into one of the largest fertility groups in the world. The company provides a wide range of services, including in vitro fertilization (IVF), egg donation, pre-implantation genetic testing (PGT), and fertility preservation. Following a 2017 merger with the US-based Reproductive Medicine Associates of New Jersey (RMANJ), the group became IVI-RMA Global. In 2022, the private equity firm KKR acquired the company to expand its international footprint. IVI is also recognized for its significant scientific contributions, publishing numerous peer-reviewed studies that have advanced the field of embryology and maternal-fetal medicine.